Céline A. Blache

Learn More
Cancer vaccine therapies have only achieved limited success when focusing on effector immunity with the goal of eliciting robust tumor-specific T-cell responses. More recently, there is an emerging understanding that effective immunity can only be achieved by coordinate disruption of tumor-derived immunosuppression. Toward that goal, we have developed a(More)
Generating antitumor responses through the inhibition of tumor-derived immune suppression represents a promising strategy in the development of cancer immunotherapeutics. Here, we present a strategy incorporating delivery of the bacterium Salmonella typhimurium (ST), naturally tropic for the hypoxic tumor environment, transformed with a small hairpin RNA(More)
Distant metastasis resulting from vascular dissemination of cancer cells is the primary cause of mortality from breast cancer. We have previously reported that E-selectin expression on the endothelial cell surface mediates shear-resistant adhesion and migration of circulating cancer cells via interaction with CD44. As a result of shedding, soluble(More)
Abbreviations: APC, antigen-presenting cell; CTL, cytotoxic T lymphocyte; CTLA-4, cytotoxic T-lymphocyte antigen 4; MDSC, myeloid-derived suppressor cell; shRNA, short hairpin RNA; siRNA, small interfering RNA; Stat3, signal transducer and activator of transcription 3; TAA, tumor-associated antigen; TAM, tumor-associated macrophage; TDLN, tumor-draining(More)
Author details Department of Pathology, University of Oklahoma Health Sciences Center, 975 NE, 10th, Oklahoma City, OK 73104, USA. Thomas Jefferson University, Pharmaceutical Sciences, 1020 Locust St, Philadelphia, PA 19107, USA. John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA. Institute of Molecular Medicine,(More)
  • 1